Öz
Dolutegravir (DTG) + lamivudin (3TC) ikili tedavi rejimi, daha önce antiretroviral tedavi almamış bireylerde birinci basamak tedavi rejimi ve virolojik baskılanma elde edilmiş olgularda geçiş rejimi olarak kılavuzlarda yer almıştır. Klinik çalışmalar ve gerçek yaşam verileri, başlangıçta veya edinilmiş M184V/I mutasyonu olan hastalarda virolojik baskılanmanın sağlanabileceğini veya sürdürülebileceğini öne sürse de, ikili rejimin bu tür olgularda kullanımı hakkında hala şüpheler vardır. Bu olgu sunumunda, direnç testi sonuçları bulunmayan, yoğun tedavi deneyimi olan ve DTG + 3TC ikili tedavisine geçtikten sonra viral baskılanması devam eden insan immün yetmezlik virüsü ile yaşayan bir birey ele alınmıştır.
Anahtar Kelimeler: Dolutegravir, lamivudin, ikili antiretroviral tedavi
Kaynakça
Pennings PS. HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep. 2013;5(Suppl 1):e5.
Parienti JJ, Fournier AL, Cotte L, Schneider MP, Etienne M, Unal G, Perré P, Dutheil JJ, Morilland-Lecoq E, Chaillot F, Bangsberg DR, Gagneux-Brunon A, Prazuck T, Cavassini M, Verdon R, Hocqueloux L. Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication. Open Forum Infect Dis. 2021;8:ofab316.
Parienti JJ, Haberer JE. Forgiveness of an intermittent HIV treatment strategy. Lancet HIV. 2022;9:e68-9.
Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85:1-18.
Sun J, Lu H. Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine. Drug Discov Ther. 2021;15:225-6.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143-55. Erratum in: Lancet. 2018.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial. Clin Infect Dis. 2022:ciac130.
van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis. 2020;71:1920-9.
European AIDS Clinical Society. EACS guidelines v11.0. October. 2021:17,143. Last accessed date: 2022 Oct 7. Available from: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Last accessed date: 2022 Oct 7. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescentarv. pdf.
Quesada PR, Esteban LL, García JR, Sánchez RV, García TM, Alonso-Vega GG, Ferrández JS. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37:865-72.
McLaughlin MM, Guerrero AJ, Merker A. Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV. Drugs Context. 2018;7:212519.
Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, d’Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17:551.
Luber AD. Genetic barriers to resistance and impact on clinical response. MedGenMed. 2005;7:69.
Delaugerre C. Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor. Med Mal Infect. 2010;40 Suppl 1:S1-10.
Jabłonowska E, Siwak E, Bociąga-Jasik M, Gąsiorowski J, Kalinowska A, Firląg Burkacka E, Wójcik-Cichy K, Piątek A, Cielniak I, Horban A. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PLoS One. 2019;14:e0210476.
Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E, Vecchiet J. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol. 2013;85:755-9.
Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One. 2013;8:e52562.
The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021;35:869-82.
Zeuli J, Rizza S, Bhatia R, Temesgen Z. Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019;55:669-82.
Surial B, Béguelin C, Chave JP, Stöckle M, Boillat-Blanco N, Doco-Lecompte T, Bernasconi E, Fehr J, Günthard HF, Schmid P, Walti LN, Furrer H, Rauch A, Wandeler G; and the Swiss HIV Cohort Study. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. J Acquir Immune Defic Syndr. 2020;85:227-32.
Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, Wit F, Lehmann C, d’Arminio Monforte A, Miró JM, Castagna A, Spagnuolo V, Sönnerborg A, Law M, Hutchinson J, Chkhartishvili N, Bolokadze N, Wasmuth JC, Stephan C, Vannappagari V, Rogatto F, Llibre JM, Duvivier C, Hoy J, Bloch M, Bucher HC, Calmy A, Volny Anne A, Pelchen-Matthews A, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021;73:e2323-33.
Scholten S, Noe S, Wyen C, Beer D, Postel N, Degen O, Pauli R, Hillenbrand H, Westermayer B,Dymek KM, Scherzer J. 12-month outcomes of dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated PLWH in Germany: Real-world data from the German URBAN cohort. HIV Med.2021(Suppl 3):111-2.
Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, d’Ettorre G, Giacometti A, Cossu MV, Borghetti A, Gennari W, Mussini C, Borghi V, Di Giambenedetto S. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54:728-34.
Haidari G, Barchi W, Chilton D, Kulasegaram R. Dolutegravir (DTG) + lamivudine (3TC) in People living with HIV (PLWH) as a switch or start: a London based experience. HIV Med. 2021;Suppl 3:112-3.
Liaño JP, Arquelladas SS, Lopez-Cortes L, Santos J, Gomez MÁ, Ferra S, Valecillos CG, Tenorio CH. DOLAM study 200: Effectiveness, safety and economic evaluation of dual therapy with dolutegravir plus lamivudine in treatment-experienced HIV patients. HIV Med. 2021;Suppl 3:99-100.
Tagliaferri G, Gazzola L, Mule G, Copes A, Bai F, Marchetti G, d’Armino Monforte A. Dolutegravir-based therapy (DT): Real-life data in c-ART experienced patients. HIV Med. 2021;Suppl 3:79-80.
Mussini C, Henegar C, Assoumou L, deWit S, Johnson M, Roldan E, Ragone L, vanWyk J, Aboud M, Fletcher C, Duffy A, Pozniak A, Vannappagari V. Highly effective two-drug regimens of an integrase inhibitor and reverse transcriptase inhibitor in real-world setting-Data from COMBINE-2 study. HIV Med. 2021;Suppl 3:106.
Blick G, Cerreta E, Mancini G, Cosenza A, Fang L, Solar SD. A prospective study switching to DTG/3TC from 3- or 4-drug ART for maintenance of viral suppression with historic M184V/I mutation and prior virological failures: 48-week primary end point results. HIV Med. 2021;Suppl 3:122-3.
Rolle CP, Nguyen V, Hinestrosa F, DeJesus E. Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV. AIDS Res Ther. 2021;18:26.
Oliveira M, Ibanescu RI, Pham HT, Brenner B, Mesplède T, Wainberg MA. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. AIDS. 2016;30:2267-73.
